M23-698 HS

Let’s Step Up to HS

Hidradenitis suppurativa (HS) can feel limiting at times, but it can’t stop you from looking for answers. Participate in clinical research to join a community of people looking for a better future for their HS.

You may be able to participate
in the M23-698 HS Research Study if you:

Are 12 years old or older

Have been diagnosed with HS for at least 6 months

Haven’t seen enough improvement from a previous HS treatment

If you are interested in participating, the study doctor or staff will review additional study criteria with you.

Eligibile participants may be compensated for travel and expenses.

About Hidradenitis Suppurativa (HS)1

  • HS is a skin condition that causes painful bumps (nodules) on the skin
  • These bumps or nodules will usually develop on the skin of the armpits, groin, buttocks, and breasts
  • HS bumps can be painful and cause scarring, drainage, and unpleasant odors
  • HS symptoms usually begin between puberty and age 40
  • As many as 4% of people worldwide are estimated to have HS

We need clinical research to find safe and effective treatment options for people with HS.

This is the goal of the M23-698 HS Research Study.

About the M23-698 HS Research Study

The M23-698 HS Research Study is a clinical research study designed to evaluate the safety and efficacy of an investigational product compared to a placebo in reducing symptoms and improving the quality of life for participants living with HS. Participants will receive either the investigational product or a placebo (something that looks like the investigational product but has no effect on the body), both administered orally (by mouth).

Participants will be assigned randomly (by chance) to receive either the investigational product or a placebo for 16 weeks. After this, a participant’s continued study treatment will be determined by their clinical symptoms, test results, and examinations. Participants will receive the investigational product or placebo for another 20 weeks, and this treatment may be assigned randomly (by chance) again. All participants will then enter a 68-week extension period where they will continue receiving the same investigational product or placebo they were taking at the end of the second period. If a participant’s symptoms do not improve enough after participating in the study for 28 weeks, they may receive the investigational product based on specific criteria.
Consider joining the M23-698 HS Research Study today.
M23-698 HS
Hidradenitis Suppurativa Clinical Research Study
© 2023–2024 Clinical Trial Media. All Rights Reserved.
All images depicted on this website contain models and are being used for illustrative purposes only.

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies, and cookies can only be disabled by changing your browser preferences. 

For more detailed information on the cookies we use, please check our Privacy Policy

By continuing to access this website, you are giving us consent to collect cookies.

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies, and cookies can only be disabled by changing your browser preferences. 

For more detailed information on the cookies we use, please check our Privacy Policy

By continuing to access this website, you are giving us consent to collect cookies.